Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care
Long-acting injectable (LAI) formulations have revolutionized veterinary pharmaceuticals by improving patient compliance, minimizing dosage frequency, and improving therapeutic efficacy. These formulations utilize advanced drug delivery technologies, including microspheres, liposomes, oil solutions/...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/17/5/626 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849327332930617344 |
|---|---|
| author | HariPriya Koppisetti Sadikalmahdi Abdella Deepa D. Nakmode Fatima Abid Franklin Afinjuomo Sangseo Kim Yunmei Song Sanjay Garg |
| author_facet | HariPriya Koppisetti Sadikalmahdi Abdella Deepa D. Nakmode Fatima Abid Franklin Afinjuomo Sangseo Kim Yunmei Song Sanjay Garg |
| author_sort | HariPriya Koppisetti |
| collection | DOAJ |
| description | Long-acting injectable (LAI) formulations have revolutionized veterinary pharmaceuticals by improving patient compliance, minimizing dosage frequency, and improving therapeutic efficacy. These formulations utilize advanced drug delivery technologies, including microspheres, liposomes, oil solutions/suspensions, in situ-forming gels, and implants to achieve extended drug release. Biodegradable polymers such as poly(lactic-<i>co</i>-glycolic acid) (PLGA), and polycaprolactone (PCL) have been approved by the USFDA and are widely employed in the development of various LAIs, offering controlled drug release and minimizing the side effects. Various classes of veterinary medicines, including non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, and reproductive hormones, have been successfully formulated as LAIs. Some remarkable LAI products, such as ProHeart<sup>®</sup> (moxidectin), Excede<sup>®</sup> (ceftiofur), and POSILACTM (recombinant bovine somatotropin), show clinical relevance and commercial success. This review provides comprehensive information on the formulation strategies currently being used and the emerging technologies in LAIs for veterinary purposes. Additionally, challenges in characterization, in vitro testing, in vitro in vivo correlation (IVIVC), and safety concerns regarding biocompatibility are discussed, along with the prospects for next-generation LAIs. Continued advancement in the field of LAI in veterinary medicine is essential for improving animal health. |
| format | Article |
| id | doaj-art-7129fd1633bc48e1b8b6341a85bcbf58 |
| institution | Kabale University |
| issn | 1999-4923 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj-art-7129fd1633bc48e1b8b6341a85bcbf582025-08-20T03:47:54ZengMDPI AGPharmaceutics1999-49232025-05-0117562610.3390/pharmaceutics17050626Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary CareHariPriya Koppisetti0Sadikalmahdi Abdella1Deepa D. Nakmode2Fatima Abid3Franklin Afinjuomo4Sangseo Kim5Yunmei Song6Sanjay Garg7Centre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, AustraliaCentre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, AustraliaCentre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, AustraliaCentre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, AustraliaCentre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, AustraliaCentre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, AustraliaCentre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, AustraliaCentre for Pharmaceutical Innovation, Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, AustraliaLong-acting injectable (LAI) formulations have revolutionized veterinary pharmaceuticals by improving patient compliance, minimizing dosage frequency, and improving therapeutic efficacy. These formulations utilize advanced drug delivery technologies, including microspheres, liposomes, oil solutions/suspensions, in situ-forming gels, and implants to achieve extended drug release. Biodegradable polymers such as poly(lactic-<i>co</i>-glycolic acid) (PLGA), and polycaprolactone (PCL) have been approved by the USFDA and are widely employed in the development of various LAIs, offering controlled drug release and minimizing the side effects. Various classes of veterinary medicines, including non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, and reproductive hormones, have been successfully formulated as LAIs. Some remarkable LAI products, such as ProHeart<sup>®</sup> (moxidectin), Excede<sup>®</sup> (ceftiofur), and POSILACTM (recombinant bovine somatotropin), show clinical relevance and commercial success. This review provides comprehensive information on the formulation strategies currently being used and the emerging technologies in LAIs for veterinary purposes. Additionally, challenges in characterization, in vitro testing, in vitro in vivo correlation (IVIVC), and safety concerns regarding biocompatibility are discussed, along with the prospects for next-generation LAIs. Continued advancement in the field of LAI in veterinary medicine is essential for improving animal health.https://www.mdpi.com/1999-4923/17/5/626long-acting injectionsveterinary medicineextended drug releasebiocompatibility |
| spellingShingle | HariPriya Koppisetti Sadikalmahdi Abdella Deepa D. Nakmode Fatima Abid Franklin Afinjuomo Sangseo Kim Yunmei Song Sanjay Garg Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care Pharmaceutics long-acting injections veterinary medicine extended drug release biocompatibility |
| title | Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care |
| title_full | Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care |
| title_fullStr | Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care |
| title_full_unstemmed | Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care |
| title_short | Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care |
| title_sort | unveiling the future opportunities in long acting injectable drug development for veterinary care |
| topic | long-acting injections veterinary medicine extended drug release biocompatibility |
| url | https://www.mdpi.com/1999-4923/17/5/626 |
| work_keys_str_mv | AT haripriyakoppisetti unveilingthefutureopportunitiesinlongactinginjectabledrugdevelopmentforveterinarycare AT sadikalmahdiabdella unveilingthefutureopportunitiesinlongactinginjectabledrugdevelopmentforveterinarycare AT deepadnakmode unveilingthefutureopportunitiesinlongactinginjectabledrugdevelopmentforveterinarycare AT fatimaabid unveilingthefutureopportunitiesinlongactinginjectabledrugdevelopmentforveterinarycare AT franklinafinjuomo unveilingthefutureopportunitiesinlongactinginjectabledrugdevelopmentforveterinarycare AT sangseokim unveilingthefutureopportunitiesinlongactinginjectabledrugdevelopmentforveterinarycare AT yunmeisong unveilingthefutureopportunitiesinlongactinginjectabledrugdevelopmentforveterinarycare AT sanjaygarg unveilingthefutureopportunitiesinlongactinginjectabledrugdevelopmentforveterinarycare |